BioWorld

Dec. 28, 2004

View Archived Issues

FDA Turns Down Cellegy's Cellegesic For Anal Fissures

Shares of Cellegy Pharmaceuticals Inc. sank nearly 45 percent Monday, following news late last week that the FDA issued a not approvable letter for the company's anal fissure product, Cellegesic. (BioWorld Today) Read More

Sunesis Planning For $86M IPO; Funds Partially For Clinical Trials

Read More

In Breast, Prostate Cancers, It's Guilt By Association For ICAMs

Read More

EntreMed Pockets $14M Via Stock, Warrants Placement

Read More

Other News To Note

Read More